WisBusiness: Exact Sciences purchasing Genomic Health for $2.8 billion

WisBusiness: Exact Sciences purchasing Genomic Health for $2.8 billion

Exact Sciences is purchasing a California company called Genomic Health for $2.8 billion, expanding its reach in the cancer diagnostics market.

The company’s colon cancer test, called Cologuard, will be sold alongside Genomic Health’s Oncotype IQ suite of products, which help guide treatment decisions for cancer patients. The acquisition is expected to be finished by the end of the year.

“With our collective resources and broader platform, we will be able to provide our existing tests to more people, while also accelerating the development and launch of future cancer diagnostic tests,” said Kevin Conroy, chairman and CEO of the Madison company.

Read the full article here.